Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies

Mireia Pesarrodona, Toni Jauset, Zamira V. Díaz-Riascos, Alejandro Sánchez-Chardi, Marie Eve Beaulieu, Joaquin Seras-Franzoso, Laura Sánchez-García, Ricardo Baltà-Foix, Sandra Mancilla, Yolanda Fernández, Ursula Rinas, Simó Schwartz, Laura Soucek, Antonio Villaverde, Ibane Abasolo, Esther Vázquez

Research output: Contribution to journalArticleResearch

13 Citations (Scopus)

Abstract

© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.
Original languageEnglish
Article number1900849
JournalAdvanced Science
Volume6
DOIs
Publication statusPublished - 1 Sep 2019

Keywords

  • biofabrication
  • cancer therapy
  • functional amyloids
  • inclusion bodies
  • protein drug release

Fingerprint Dive into the research topics of 'Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies'. Together they form a unique fingerprint.

Cite this